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A B S T R A C T
The enzyme 5α-reductase (5αR) catalyzes the conversion of progesterone and testosterone into neuroactive steroids im-
plicated in a wide array of behavioral functions. The prototypical 5αR inhibitor, finasteride (FIN), is clinically approved
for the treatment of androgenic alopecia and benign prostatic hyperplasia. Recent evidence has shown that FIN, albeit
generally well tolerated, can induce untoward psychological effects in a subset of patients; furthermore, this drug may
have therapeutic efficacy for a number of different neuropsychiatric conditions, ranging from Tourette syndrome to schiz-
ophrenia. In rat models of these conditions, FIN has been shown to block the effects of dopamine receptors in the nucleus
accumbens (NAcc), a key terminal of the dopamine mesolimbic system. The biological underpinnings of these effects,
however, remain mostly elusive. To elucidate the neurochemical networks that may be responsible for the behavioral ef-
fects of FIN, we evaluated the proteomic profile of the NAcc following acute (100 mg/kg, IP) and subchronic (7 days;
100 mg/kg/day, IP) treatment with this drug, in comparison with vehicle treatment (n = 5/group). Two-dimensional elec-
trophoresis (2-DE) analysis coupled to mass spectrometry revealed significant changes in the expression of nine proteins
(CRMP2, PSMD1, STX18, KCNC3, CYP255, GABRP, GABT, PRPS1, CYP2B3), which were further analyzed by on-
tological classification (PANTHER). These results point to a number of novel potential chemical targets of FIN, and may
help elucidate the underpinnings of FIN’s behavioral effects and therapeutic potential for neuropsychiatric disorders.
© 2016 Published by Elsevier Ltd.
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1. Introduction
The enzyme 5α-reductase (5αR) catalyzes the rate-limiting step
in the irreversible saturation of the 4,5 double bond of the A ring
of Δ4-3 ketosteroids, such as progesterone and testosterone (Paba et
al., 2011). The products of this enzymatic process include a number
of neuroactive steroids, including 5α-dihydroprogesterone (DHP) and
5α-dihydrotestosterone (DHT); in the brain, these steroids are further
converted into key neurosteroid metabolites implicated in behavioral
regulation, such as 3α,5α,tetrahydroprogesterone (allopregnanolone,
AP) and 3α,5α,androstanediol (3α-diol) (Barbaccia, 2004; Frye et al.,
2010). The prototypical 5αR inhibitor, finasteride (FIN), is currently
approved for the treatment of a number of conditions associated with
high DHT, such as benign prostatic hyperplasia (BPH) and androge
⁎ Corresponding author at: Istituto Sperimentale Italiano “Lazzaro Spallanzani”
Milano, Sezione di Proteomica c/o Dipartimento di Medicina Veterinaria, Università
degli Studi di Milano, via Celoria 10, 20133 Milano, Italy.
Email address: paola.roncada@istitutospallanzani.it, paola.roncada@gmail.com
(P. Roncada)
netic alopecia. Although FIN use is typically well-tolerated, its use for
either BPH or alopecia has been linked to disturbances in ejaculation
and erection, as well as loss of libido (Carbone and Hodges, 2003;
Kaufman et al., 1998; McClellan and Markham, 1999). Clinical trials
have shown that these side effects affect ∼15% patients, in compari-
son with 7% of placebo-treated counterparts (Traish et al., 2011). Re-
cent lines of evidence have also shown that FIN can induce enduring
psychoendocrinological side effects in vulnerable patients, including
depression and reduction of libido (Irwig, 2012; Rahimi-Ardabili et
al., 2006; Traish et al., 2015). This symptomatology can persist after
therapy cessation, a condition that has been recently termed “post-fi-
nasteride syndrome” (PFS) and may be underpinned by persistent
changes in the neurosteroid profile in CSF and plasma (Caruso et al.,
2015).
Complementary to this concept, FIN may have therapeutic poten-
tial for several neuropsychiatric conditions characterized by informa-
tion-processing deficits and poor behavioral control, encompassing
Tourette syndrome to schizophrenia and problem gambling in Parkin-
son’s disease patients (Bortolato et al., 2012, 2007; Koethe et al.,
2008; Paba et al., 2011). In parallel with these observations, FIN was
shown to ameliorate several behavioral abnormalities exhibited by rat
http://dx.doi.org/10.1016/j.psyneuen.2016.10.001
0306-4530/© 2016 Published by Elsevier Ltd.
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models of the conditions shown by Bortolato and coworkers
(Bortolato et al., 2008; Frau et al., 2015, 2016), likely by reducing the
effects of dopamine signaling at the level of D1, and possibly D3, re-
ceptors (Frau et al., 2016). Consistently with these findings, the an-
tipsychotic-like actions of FIN have been shown to be primarily con-
tributed by the nucleus accumbens (NAcc) (Devoto et al., 2012), the
major terminal of the dopamine mesolimbic pathway. These mecha-
nisms may also account for the lowering of mood and libido, given the
importance of the dopaminergic signaling in the NAcc in the regula-
tion of sex drive, reward, and motivation (Giuliano and Allard, 2001;
Ikemoto and Panksepp, 1999). While these premises point to FIN as
a promising option in neuropsychiatric therapy, the specific mecha-
nisms whereby this drug may reduce dopaminergic signaling remain
elusive, partially reflecting our limited knowledge of the molecular
targets of neurosteroids in the brain. Based on this background, the
present study was aimed at the investigation of the proteomic profile
of the NAcc of rats treated with either acute or subchronic FIN treat-
ment. Specifically, the intraperitoneal dose of FIN that was admin-
istered was 100 mg/kg, which was previously shown to induce a ro-
bust reduction of allopregnanolone levels, increase concentrations of
pregnenolone and progesterone (Frau et al., 2015), and counter the ef-
fects of dopaminergic agonists across multiple behavioral paradigms
(Bortolato et al., 2008; Devoto et al., 2012).
2. Materials and methods
2.1. Animals and treatment
A total of 15 Sprague–Dawley male rats (Harlan Italy, S. Pietro al
Natisone, Italy), weighing 200–250 g were used for these experiments.
Animals were group-housed in cages (n = 3/cage) with ad libitum ac-
cess to food and water. Rooms were maintained at 22 ± 0.2 °C on re-
versed 12-h light/dark cycle (with lights off at 07:00 PM). All exper-
imental procedures were in compliance with the National Institutes of
Health guide for the care and use of Laboratory animals and approved
by the local Institutional Animal Use Committee. This study was car-
ried out in agreement with ARRIVE guidelines.
2.2. Drugs and treatments
FIN (Sigma-Aldrich, Milan, Italy) was suspended in a vehicle
(VEH) solution containing 5% Tween 80 and 95% saline, and admin-
istered intraperitoneally (IP) at the dose of 100 mg/kg (in an injection
volume of 2 ml/kg body weight). In every cage, each rat was subjected
to one of the following three treatments: 1) 7-day administration of
VEH (n = 5); 2) 6-day administration of VEH, followed by FIN on the
seventh day (n = 5); 3) 7-day administration of FIN (n = 5). All efforts
were made to minimize animal suffering. One hour following the last
treatment, rats were sacrificed and their NAcc was harvested, rapidly
frozen in dry ice, and stored at −80 °C until analysis.
2.3. Protein extraction and 2-dimensional electrophoresis (2-DE)
NAcc samples were harvested according to the indication of the
atlas of Paxinos and Watson (1998). Proteins were extracted from
all NAcc tissue samples using a variant of the protocol described in
(Roncada et al., 2009). Briefly, tissues were weighed and suspended
(1:10, w/v) in a solution of 7 M urea, 2 M thiourea, 2% 3-[(3-Cholami-
dopropyl)dimethylammonio-1-propanesulfonate (CHAPS), 2% Triton
X-100, 2%(v/v) Ampholine pH 3.5–10. The suspensions
were subjected to five cycles of bead beating (Biospec Products Inc,
USA) for 1 min at 4000 rpm/min and finally centrifuged at 14
000g and 4 °C for 30 min to remove cellular debris and insoluble ma-
terials and the supernatants were collected. Protein concentration on
supernatants was determined using the 2D Quant Kit (GE Health-
care, Little Chalfont, UK). Seven-cm immobilized pH gradient (IPG)
strips with a linear pH range of 4–7 (GE Healthcare) were rehydrated
overnight in 125 μl of buffer containing 7 M urea, 2 M thiourea 2%
CHAPS, 1% DTT, 2% ampholine pH 3.5–10. 100 μg of protein sam-
ple were loaded on each IPG strip using cup loading at the cathodic
side (Piras et al., 2012). Isoelectric focusing was performed using an
Ettan IPGphor III IEF system (GE Healthcare) at 20° C with a cur-
rent of 50 μA per strip. For IEF the following protocol was used: 30 V
(4 h), 50 V (3 h), 100 V (3 h), 500 V (3 h), 1000 V (3 h), 3000 V (3 h),
4000 V (3 h), 6000 V (3 h) and 8000 V (8 h) (Soggiu et al., 2013). Af-
ter the first dimension, IPG strips were equilibrated twice with a solu-
tion containing 6 M urea, 2% SDS, 50 mM Tris–HCl pH 8.8 and 30%
glycerol, for 15 min, under gentle stirring. For the first equilibration
step was used 1% DTT and for the second 2.5% iodoacetamide. The
second dimension was performed using homemade 12% acrylamide
vertical SDS-PAGE slab gels on a Mini Protean Tetra cell (BioRad,
Hercules, CA). IPG strips were put on top of the SDS gels and were
poured up to 1 cm from the top of the plates and then sealed with 1 ml
of a solution containing 0.5% low-melting-point agarose diluted in hot
SDS running buffer (25 mM Tris–HCl pH 8.3, 192 mM glycine, 0.1%
SDS). Molecular weight protein markers (Invitrogen, Carlsbad, CA)
were applied on one end of the IPG strips. In the second dimension,
gels were run until the bromophenol blue front-line came out of the
gel. After runs, gels were stained with colloidal Coomassie and digi-
tized with ImageScanner III (GE Healthcare) at 600 dpi.
2.4. Image analysis and spots identification
Gel images were imported into Progenesis SameSpots (v4.6; To-
tallab Ltd, Newcastle, UK) for analysis. All imported images were
processed to check image quality (saturation, dimension, background).
The aligned images were then automatically analyzed using the 2D
analysis module for spot detection, background subtraction, normal-
ization, and spot matching, and all spots were manually reviewed and
validated to ensure proper detection and matching. Differentially ex-
pressed spots with a p value < 0.05 and a power value >0.8 were se-
lected for the identification by mass spectrometry.
2.5. Protein identification by MALDI-TOF/TOF MS analysis
Protein identification was performed according to protocols de-
scribed by (Piras et al., 2015). Briefly, single spots were excised
from gels and gradually dehydrated. After reduction and alkylation,
single spots were digested with a solution of 0.01 μg/μl of porcine
trypsin (Promega, Madison, WI) at 37 °C overnight. (Arioli et al.,
2009). The reaction was stopped with 1% TFA in H2O (v/v). Pep-
tides were desalted and concentrated by C18 ZipTip (Millipore) and
co-crystallized with a solution of 0.5 mg/ml α-ciano-4-hydroxycin-
namic acid dissolved in 50% acetonitrile, 0.05% TFA on a Ground
Steel plate (Bruker-Daltonics, Bremen, Germany) previously spotted
with a thin layer of 10 mg/ml α-ciano-4-hydroxycinnamic acid dis-
solved in Ethanol/Acetonitrile/0.1% (v/v) TFA in H2O. MS raw data
were acquired with an Ultraflex III MALDI-TOF/TOF spectrometer
(Bruker Daltonics) in positive reflectron mode. External calibration
was performed using the standard peptide mixture calibration (m/z:
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1046.5418, 1296.6848, 1347.7354, 1619.8223, 2093.0862,
2465.1983, 3147.4710; Bruker-Daltonics). FlexAnalysis 3.3 software
(Bruker-Daltonics) was used for the selection of the monoisotopic
peptide masses of each mass spectra. Internal calibration was per-
formed on autolysis peaks of porcine trypsin (m/z: 842.509 and
2211.104). After exclusion of contaminant ions (known matrix and
human keratin peaks), the created peak lists were analyzed by MAS-
COT v.2.4.1 algorithm (www.matrixscience.com) against SwissPro-
t_2013_05 database restricted to Rattus norvegicus taxonomy (7867
sequences). The query for Peptide Mass Fingerprinting (PMF) analy-
sis was performed with carbamidomethylation of cysteines as fixed
modification, oxidation of methionines as variable modification, one
missed cleavage site allowed for trypsin and 70 ppm as maximal tol-
erance. Mascot protein scores greater than 52 were considered signifi-
cant (p < 0.05) for protein identification assignment. To confirm PMF
analysis, the instrument was switched to LIFT mode and subsequently
MS/MS spectra were acquired (Piras et al., 2015). For the fragmen-
tation, precursor ions were manually selected and the precursor mass
window was automatically set.
The analyses of each MS/MS spectra (spectra baseline subtraction,
smoothing Savitsky–Golay and centroiding) were carried out by Flex
Analysis 3.3 software (Bruker Daltonics). These parameters used for
database search were: carbamidomethylation of cysteines and oxida-
tion on methionine respectively for fixed and variable modifications,
one missed cleavage, 50 ppm for the mass tolerance for precursor
ions and 0.4 Da for fragments. The taxonomy was restricted to Rattus
norvegicus. The confidence interval for protein identification was set
to 95% (p < 0.05) and only peptides with Individual ions scores >22,
that indicate identity or extensive homology, were considered.
2.6. Bioinformatics analysis
To identify Gene Ontology (GO) classes and biologically relevant
molecular pathways from our data, proteomics datasets were analyzed
using the PANTHER (Protein ANalysis THrough Evolutionary Re-
lationships) Classification System (version 10, Released 2015-05-15)
(Mi et al., 2016). In particular, the PANTHER statistical overrepre-
sentation Test (release 20160321) was applied to retrieve statistically
significant (p-value < 0.05) over-represented or enriched functional
classes and pathways.
2.7. Statistical analyses
All comparisons between treatment groups were calculated on
PRISM 5 (GraphPad software , USA) applying one-way ANOVA,
followed by Tukey’s test for post hoc comparisons. A p-value of 0.05
was considered statistically significant.
3. Results
All proteins were separated by 2-DE and identified by
MALDI-TOF/TOF mass spectrometry (Fig. 1). As shown in Table
1, this analysis revealed that either acute or subchronic treatment
with FIN elicited significant changes in the expression of nine pro-
teins in the NAcc (Fig. 2). Specifically, this analysis detected that
acute FIN administration led to the increased expression of the col-
lapsin response mediator protein 2 (CRMP2), Syntaxin-18 (STX18),
the non-ATPase regulatory subunit of the 26S proteasome (PSMD1)
as well as Cytochrome P450 2B3 (CYP2B3) (P < 0.05 for all compar-
isons with VEH-treated controls). In contrast, the same treatment led
to the decrease of GABA transaminase (GABT) (P < 0.05).
The 7-day FIN treatment led to the decreased expression of the
voltage-gated potassium channel KCNC3, Cytochrome P450 2C55
Fig. 1. Representative two dimensional map of proteins from rat nucleus accumbens. Proteins were separated on a pH 4–7 immobilized pH gradient strip, followed by a 12% poly-
acrylamide gel electrophoresis, as described in Materials and methods. After electrophoresis the gels were stained with colloidal coomassie blue and the statistically significant protein
spots on the image were analyzed by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF/TOF MS). Spot numbers on the image refer to Table
1. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 1
Protein identification by MALDI-TOF/TOF MS analysis.
Spot
no. Protein descriptiona Accession no.b
Fold
change
Theoretical
Mr(kDa)/pI PMF MS/MS
Mascot
scorec
%Seq.
coveraged
Matched
peptidese Peptide sequencef
Mascot
scoreg m/zh
1549 Dihydropyrimidinase-related
protein 2
DPYL2_RAT 1.4 62.6/5.95 106 26 13/49 472-KPFPDFVYK-480 80 1140.62
452-IVLEDGTLHVTEGSGR-467 80 1682.87
1084 Potassium voltage-gated
channel subfamily C member
3
KCNC3_RAT 2 95.6/6.62 125 27 19/71 317-IPLDVGHRGAGNSTTTAK-334 92 1794.83
1519 Cytochrome P450 2C55 CP255_RAT 1.5 56.6/6.51 214 77 31/126 453-NCIGKQFAMNELK-465 80 1553.89
825 26S proteasome non-ATPase
regulatory subunit 1
PSMD1_RAT 1.8 106.7/5.25 168 23 25/59 153-SATLVLAYLMIHK-165 86 1475.78
1748 Gamma-aminobutyric acid
receptor subunit pi
GBRP_RAT 1.8 50.8/8.03 116 45 14/67 92-WTDPRLVFEGNK-103 76 1461.80
1785 4-aminobutyrate
aminotransferase,
mitochondrial
GABT_RAT 1.9 57.2/8.15 186 42 21/59 174-TIFMWYR-180 80 1016.50
368-EEFRPSAPYR-377 110 1251.61
2394 Ribose-phosphate
pyrophosphokinase 1
PRPS1_RAT 1.4 35.3/6.51 160 47 13/29 85-VTAVIPCFPYAR-96 80 1394.71
3025 Syntaxin-18 STX18_RAT 1.4 38.7/5.56 180 52 22/77 265-LQEIFTEK-272 70 1007.55
3028 Cytochrome P450 2B3 CP2B3_RAT 1.2 56.86/6.39 117 37 14/49 158-IMADSVNIMLDK-169 70 1365.64
Name of identified proteins; bAccession No. according to SwissProt database; cPeptide Mass Fingerprinting score calculated by MASCOT 2.4.1 algorithm (www.matrixscience.com)
after database search; d sequence coverage; e Number of experimental peptides matched versus searched peptides; faminoacidic sequence of the peptides identified by MS/MS analysis
and grelated score calculated by MASCOT 2.4.1 algorithm. Underlined letter indicates oxidation of methionine residue; h Monoisotopic masses of the parent ions used for MS/MS
analysis.
Fig. 2. Finasteride (FIN) treatment resulted in significant differences in the expression of nine proteins of the nucleus accumbens. Data are presented as mean ± SD. *, P < 0.05; **,
P < 0.01 in comparison with vehicle-treated rats; V, vehicle; A, acute (i.e., 6 days of vehicle followed by one day of FIN); S, sub-chronic (7 days of FIN).
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(CYP255), the π subunit of the GABA-A receptor (GBRP), phospho-
ribosyl pyrophosphate synthetase-1 (PRPS1) and GABT (Ps < 0.05),
while it significantly increased the levels of CYP2B3 (P < 0.05).
As shown in Table 2, gene ontology analyses by PANTHER re-
vealed that the proteins affected by FIN treatment belong to key func-
tional pathways underlying signaling processes in the central nervous
system (synaptic transmission, exocytosis, ion transport), or were in-
cluded in regulatory pathways for neurosteroid synthesis (steroid and
fatty acid conversion).
Among the pathways and molecular functions indicated by PAN-
THER, a number of processes appear to be relevant to the potential
role of FIN in behavioral regulation and dopamine signaling modula-
tion, such as the synthesis and catabolism of GABA, as well as the
axonal structure and degradation ubiquitin-proteasome dependent and
the regulation of the activity of GABA-A receptor and voltage-gated
ion channels (Tables 3 and 4).
4. Discussion
The results of this study showed that the administration of an acute,
high dose of FIN (100 mg/kg, IP) associated with marked behavioral
effects (Bortolato et al., 2008; Frau et al., 2015) led to a significant
increase in the expression of four proteins (CRMP2, STX18, PSMD1,
CYP2B3), as well as the reduction of GABT levels, in the NAcc;
conversely, subchronic FIN treatment led to the decrease of five pro-
teins (KCNC3, CYP255, PRPS1, GBRP, and GABT) and a significant
up-regulation of CYP2B3. Gene ontology analyses, as highlighted
by PANTHER, indicated that FIN treatment results in over-repre-
sentation of six different pathways compared to the control, includ-
ing GABA synthesis and degradation, as well as pyrimidine metabo-
lism. These alterations were associated with multiple key biological
processes, including synaptic transmission and fatty acid metabolism,
as well as the regulation of the steroid biosynthetic process.
Table 2
PANTHER overrepresented pathways related to the finasteride treatment.
PANTHER Pathways Ref
Our
list Expected
Fold
Enrichment +/−
P
value
Pyrimidine Metabolism 12 2 0.00 >100 + ***
Aminobutyrate degradation 4 1 0.00 >100 + **
Gamma-aminobutyric acid
synthesis
5 1 0.00 >100 + **
Axon guidance mediated by
semaphorins
22 1 0.01 >100 + **
De novo purine biosynthesis 41 1 0.02 61.40 + **
Ubiquitin proteasome
pathway
66 1 0.03 38.14 + *
Unclassified 19872 5 7.89 0.63 – *
The first column contains the name of the annotation data category. The second column
(REF) contains the number of genes in the Rattus norvegicus gene reference list that
map to each particular annotation data category in the first column. The third column
(our list) contains the number of genes in our dataset that map to the annotation data
category. The fourth column contains the expected value, which is the number of genes
that we expect in our list for each category, based on the reference list. The fifth column
shows the Fold Enrichment of the genes observed in the analyzed protein list over the
expected (all the proteins in our list divided by the expected number). If it is greater
than one, it indicates that the category is overrepresented in our protein list. Conversely,
the category is under-represented if it is less than one. The sixth column has either a
+ or −A plus sign indicates over-representation of related category in our experiment.
Conversely, a negative sign indicates under-representation. The seventh column is the
p-value as determined by the binomial statistic. A p-value <0.05 indicates a statistically
significant value. p value legend: * P < 0.05; **P < 0.01; ***P < 0.001. Potentially
relevant processes related to FIN treatment are evidenced in bold.
Table 3
PANTHER biological process overrepresentation test, see Table 2 for column details.
GO biological process complete Ref
Our
list Expected
Fold
Enrichment +/−
P
value
epoxygenase P450 pathway 25 2 0.01 >100 + ***
arachidonic acid metabolic
process
55 2 0.02 91.54 + ***
positive regulation of aspartate
secretion
1 1 0 >100 + ***
regulation of aspartate secretion 1 1 0 >100 + ***
long-chain fatty acid metabolic
process
87 2 0.03 57.87 + ***
Eicosanoids metabolic process 96 2 0.04 52.44 + ***
fatty acid derivative metabolic
process
96 2 0.04 52.44 + ***
unsaturated fatty acid metabolic
process
104 2 0.04 48.41 + ***
gamma-aminobutyric acid
catabolic process
2 1 0 >100 + ***
5-phosphoribose 1-diphosphate
biosynthetic process
3 1 0 >100 + **
5-phosphoribose 1-diphosphate
metabolic process
3 1 0 >100 + **
gamma-aminobutyric acid
biosynthetic process
3 1 0 >100 + **
response to drug 620 3 0.25 12.18 + **
negative regulation of gamma-
aminobutyric acid secretion
4 1 0 >100 + **
positive regulation of ER to
Golgi vesicle-mediated transport
4 1 0 >100 + **
gamma-aminobutyric acid
metabolic process
5 1 0 >100 + **
regulation of neurotransmitter
levels
171 2 0.07 29.44 + **
negative regulation of
dopamine secretion
6 1 0 >100 + **
positive regulation of dopamine
metabolic process
6 1 0 >100 + **
positive regulation of
catecholamine metabolic
process
6 1 0 >100 + **
positive regulation of inhibitory
postsynaptic potential
7 1 0 >100 + **
modulation of inhibitory
postsynaptic potential
8 1 0 >100 + **
AMP biosynthetic process 8 1 0 >100 + **
neurotransmitter catabolic
process
10 1 0 >100 + **
drug catabolic process 12 1 0 >100 + **
positive regulation of glutamate
secretion
12 1 0 >100 + **
regulation of ER to Golgi
vesicle-mediated transport
13 1 0.01 >100 + **
fatty acid metabolic process 300 2 0.12 16.78 + **
positive regulation of cellular
amine metabolic process
15 1 0.01 >100 + **
negative regulation of
catecholamine secretion
16 1 0.01 >100 + **
regulation of dopamine
metabolic process
19 1 0.01 >100 + **
regulation of catecholamine
metabolic process
20 1 0.01 >100 + **
modulation of synaptic
transmission
357 2 0.14 14.1 + **
regulation of glutamate
secretion
23 1 0.01 >100 + **
regulation of dopamine
secretion
25 1 0.01 >100 + **
neurotransmitter metabolic
process
25 1 0.01 >100 + **
drug metabolic process 32 1 0.01 78.67 + *
regulation of cellular amine
metabolic process
42 1 0.02 59.94 + *
regulation of catecholamine
secretion
50 1 0.02 50.35 + *
regulation of neurotransmitter
secretion
59 1 0.02 42.67 + *
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Table 3 (Continued)
GO biological process complete Ref
Our
list Expected
Fold
Enrichment +/−
P
value
regulation of neurotransmitter
transport
70 1 0.03 35.96 + *
synaptic vesicle transport 85 1 0.03 29.62 + *
establishment of synaptic vesicle
localization
85 1 0.03 29.62 + *
synaptic vesicle localization 87 1 0.03 28.93 + *
p value legend: * P < 0.05; **P < 0.01; ***P < 0.001.
Table 4
PANTHER molecular function overrepresentation test.
GO molecular function complete Ref
Our
list Expected
Fold
Enrichment +/−
P
value
arachidonic acid epoxygenase
activity
33 2 0.01 >100 + ***
arachidonic acid monooxygenase
activity
35 2 0.01 >100 + ***
aromatase activity 38 2 0.02 >100 + ***
steroid hydroxylase activity 55 2 0.02 91.54 + ***
succinate-semialdehyde
dehydrogenase binding
1 1 0 >100 + ***
4-aminobutyrate transaminase
activity
1 1 0 >100 + ***
(S)-3-amino-2-methylpropionate
transaminase activity
1 1 0 >100 + ***
extracellular-glutamate-gated
chloride channel activity
2 1 0 >100 + ***
monooxygenase activity 132 2 0.05 38.14 + **
ribose phosphate
diphosphokinase activity
5 1 0 >100 + **
diphosphotransferase activity 8 1 0 >100 + **
AMP binding 12 1 0 >100 + **
gated channel activity 304 2 0.12 16.56 + **
GABA-A receptor activity 19 1 0.01 >100 + **
extracellular-glutamate-gated
ion channel activity
20 1 0.01 >100 + **
GABA receptor activity 22 1 0.01 >100 + **
transferase activity, transferring
nitrogenous groups
30 1 0.01 83.91 + *
passive transmembrane
transporter activity
439 2 0.17 11.47 + *
SNAP receptor activity 36 1 0.01 69.93 + *
ADP binding 40 1 0.02 62.93 + *
excitatory extracellular ligand-
gated ion channel activity
51 1 0.02 49.36 + *
GDP binding 60 1 0.02 41.96 + *
extracellular ligand-gated ion
channel activity
71 1 0.03 35.46 + *
chloride channel activity 77 1 0.03 32.69 + *
anion channel activity 87 1 0.03 28.93 + *
chloride transmembrane
transporter activity
88 1 0.03 28.61 + *
voltage-gated potassium
channel activity
89 1 0.04 28.28 + *
ion transmembrane transporter
activity
828 2 0.33 6.08 + *
inorganic anion transmembrane
transporter activity
112 1 0.04 22.48 + *
potassium channel activity 120 1 0.05 20.98 + *
p value legend: * P < 0.05; **P < 0.01; ***P < 0.001.
As mentioned above, the FIN dose used in this study was shown
to acutely reduce allopregnanolone levels and increase concentrations
of pregnenolone and progesterone in the striatum of rats (Frau et al.,
2015). Allopregnanolone and other 5αR substrates and/or products
play an important role in the functional regulation of GABA-A re-
ceptors and are posited to modulate mitochondrial and bioenergetic
functions (Klinge, 2008; Papadopoulos et al., 2006; Robertson et al.,
2006). Taken together, these results reveal that FIN may induce a dis
crete number of neurochemical alterations in the proteome of the
NAcc, which may be related to its antidopaminergic properties (Frau
et al., 2016). In the following sections, we will analyze how each of
the 9 proteins affected by FIN treatment may be relevant to the behav-
ioral and neurochemical effects of this drug.
4.1. Proteins up-regulated by FIN treatment
The only protein that was up-regulated by both acute and sub-
chronic FIN treatment was the enzyme CYP2B3, a rat-specific iso-
form of the CYP2B family (Desrochers et al., 1996) homologous to
CYP2B6 in humans. The increase in CYP2B3 after FIN treatment, ir-
respective of its duration, suggests a robust interaction between 5αRs
and this member of the cytochrome P450 family. Like other mem-
bers of this family, CYP2B3 may be upregulated to enable the me-
tabolism of either FIN itself or a number of steroid precursors that
no longer undergo conversion into their 5α-reduced metabolites. Ac-
cordingly, the CYP2B family has been shown to catalyze testosterone
16-beta hydroxylation (Ekins et al., 1998), thereby activating an al-
ternative degradation pathway for this ketosteroid. If the upregulation
of CYP2B3 is indeed important in limiting potentially detrimental ef-
fects of FIN (or possibly mediating some of its therapeutic effects), it
may be interesting to verify whether the effects of FIN may be mod-
ified by changes in CYP2B expression/activity. Of note, CYP2B6 is
implicated in the metabolism of several psychotropic drugs, such as
the antidepressant bupropion (Hesse et al., 2000), and variants of its
gene have been shown to exhibit alterations in the effects of this drug
(Zhu et al., 2012).
Our data showed that three additional proteins were down-regu-
lated by acute, but not subchronic FIN treatment:
- PSMD1, an essential component of the regulatory particle of the 26S
proteasome that recognizes and guides target proteins towards the
proteolytic site (da Fonseca and Morris, 2008). Given the crucial
role of the proteasome system in protein degradation, the FIN-in-
duced reduction in PSMD1 levels are predicted to result in the re-
duced catabolism of critical target proteins in the NAcc. In this re-
spect, it is worth noting that the 26S proteasome is implicated in the
modulation of the receptors and behavioral effects of progesterone
(Camacho-Arroyo et al., 2002; González-Flores et al., 2004).
- STX18, a member of the syntaxin family largely involved in the
progression of vesicles from the endoplasmic reticulum and the
cis-Golgi compartment (Hatsuzawa et al., 2000; Nakajima et al.,
2004). Given that both 5αR1 and 5αR2 are located in the endoplas-
mic reticulum, these data suggest that their acute inhibition may trig-
ger a number of changes in membrane transport across intracellular
compartment and vesicles;
- CRMP2, a member of the collapsin response mediator proteins that
regulates cytoskeletal dynamics and vesicle trafficking by bind-
ing to tubulin heterodimers and promoting microtubule assembly
(Fukata et al., 2002; Hensley et al., 2011); this protein also modu-
lates the function and expression of N-type calcium channels (Brit-
tain et al., 2011), which facilitate neurotransmitter release from the
presynaptic terminals (Ronzitti et al., 2014), and serve as down-
stream effectors of D2-like dopamine autoreceptors (Cabrera-Vera
et al., 2004; Canti and Dolphin, 2003; Ramanathan et al., 2008).
Taken together, this evidence suggests that the FIN-induced in-
crease in CRMP2 expression in the NAcc may lead to changes in
dopamine release from mesolimbic projections. In line with this
idea, we recently showed that acute administration of the same
doses of FIN used in this study (100 mg/kg, IP) produces a signifi-
cant increase in the accumbal dopamine release in rats (Frau et al.,
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2016). The mechanisms whereby acute FIN treatment increases
CRMP2 may reflect the action of neuroactive steroids on the multi-
ple targets of this protein. For example, interactions between preg-
nenolone and microtubules or testosterone and N-type calcium chan-
nels (Nudler et al., 2005) have been described in the literature.
CRMP2 has also been reported to interact functionally with NMDA
glutamate receptors (Brustovetsky et al., 2014), pivotal controllers
of the integration of afferent input in medium spiny neurons of the
NAcc (Wolf et al., 2005). Notably, multiple neurosteroids have been
shown to act as allosteric modulators of NMDA receptors (Borovska
et al., 2012; Elfverson et al., 2008; Johansson et al., 2010, 2008;
Sedlacek et al., 2008; Vyklicky et al., 2015). Irrespective of the
specific mechanism, it is worth noting that CRMP2 is implicated
in multiple neuropathological processes in several neuropsychiatric
disorders (Hensley et al., 2011), highlighting the possibility that
CRMP2 may act as a key effector for the behavioral effects of FIN.
4.2. Proteins down-regulated by FIN treatment
The only protein that was down-regulated by both acute and sub-
chronic FIN treatment was GABT. This mitochondrial enzyme is re-
sponsible for the main catabolic process of GABA, and its reaction
is based on the transfer of the amino group from GABA to alpha-ke-
toglutarate, with consequent production of L-glutamate and succinic
semialdehyde (Sherif, 1994; Tillakaratne et al., 1995). The rapid con-
version of this metabolite into succinic acid (which enters Krebs cy-
cle) ensures that the reaction catalyzed by GABA-T is physiologically
unidirectional. The FIN-induced decrease in GABA-T in the NAcc
is predicted to increase GABA concentrations and reduce glutamate
synthesis, thereby favoring an inhibitory tone in the brain. Given that
FIN leads to the reduction of the synthesis of AP, a positive allosteric
modulator of GABA-A receptor and negative allosteric modulator of
NMDA receptors, it is likely that the changes in GABA-T may be en-
acted by the brain as a compensatory process to offset the imbalance
in excitation/inhibition induced by FIN.
Four additional proteins were down-regulated by subchronic, but
not acute, FIN treatment:
– GBRP, the π subunit of GABA-A receptor, which was originally
characterized in the uterus (Hedblom and Kirkness, 1997), and has
been found to reduce the sensitivity of this channel to allopreg-
nanolone (Neelands and Macdonald, 1999). Although GBRP ex-
pression has been attested in the brain (Allen Brain Atlas; http:
//mouse.brain-map.org/gene/show/85019), very little is currently
known about its role in the CNS. Our finding of a reduction in
this subunit following FIN subchronic treatment opens up to the
possibility that this subunit may also be instrumental in increas-
ing the sensitivity of GABA-A to allopregnanolone and, possibly,
other neuroactive steroids, possibly as a compensatory phenomenon
for the prolonged suppression of allopregnanolone induced by sub-
chronic 5αR inhibition;
– KCNC3, the potassium channels that mediate currents (Kv3.3) char-
acterized by a marked rightward shift in their voltage dependence as
well as a very fast rate of deactivation upon repolarization (Coetzee
et al., 1999; Rudy et al., 1999). Due to these characteristics, the
inactivation of KCNC3 is highly variable, and may be modified
by numerous physiological conditions (Fernandez et al., 2003; Rae
and Shepard, 2000; Rudy et al., 1999). These unique biophysi-
cal properties may account for the bimodal behavior of the mem-
brane of medium spiny neurons in the NAcc, which oscillates be-
tween a hyperpolarized state dominated by an inwardly rectify
ing potassium current (Uchimura et al., 1989) and a more depolar-
ized state dominated by rapidly inactivating currents (Stern et al.,
1997; Wilson and Kawaguchi, 1996), such as those mediated by
KCNC3. Although little is known about the regulation of KCNC3
by steroids, our data point to the possibility that prolonged sup-
pression of neurosteroidogenesis may lead to changes in potassium
currents and electric properties of accumbal cells. In keeping with
this hypothesis, preliminary evidence has pointed to a role of neu-
rosteroids and sex hormones in the regulation of voltage-gated K+
channels (Drici et al., 1996; Wang et al., 1998; Wong et al., 2008).
– PRPS1, a key enzyme for the production of phosphoribosyl py-
rophosphate (PRPP), an essential cofactor for the de novo biosyn-
thesis of purines, pyrimidines and their nucleotides, including ATP
and GTP (Kornberg et al., 1954; Lieberman et al., 1955; Zimmer,
1998). Notably, recent evidence has shown that multiple neuros-
teroids exert beneficial bioenergetic effects on the mitochondrion
and its ability to produce ATP (Grimm et al., 2014). From this per-
spective, our finding suggests that 5αR products may have a trophic
effect on these processes by increasing the synthesis of PRPS1.
In line with this evidence, it is also worth noting that allopreg-
nanolone acts as a positive allosteric modulator of ATP-gated chan-
nels (Codocedo et al., 2009), potentially suggesting a sophisticated
relationship between neurosteroids and ATP-mediated actions.
– CYP2C55, a poorly-characterized member of the CYP2C family;
although, to the best of our knowledge, no information is currently
available on the role of CYP2C55 in the brain, or in the metabolism
of neuroactive steroids, our findings point to the possibility that this
target may be implicated in brain functions, in line with preliminary
evidence on other CYP2C members, such as CYP2C13 (Riedl et al.,
2000) and 2C9 (Gervasini et al., 2001).
4.3. Limitations and conclusions
Several limitations of the present study ought to be acknowledged.
First, our analysis could not distinguish the specific effects of FIN
in the two major subdivisions of the NAcc, the core and the shell.
These two areas serve distinct roles in the regulation of reward-seek-
ing behaviors. For example, dopamine neurotransmission in the shell
is instrumental for the appraisal of reward and encoding of moti-
vational salience for reinforcing stimuli; conversely, the core is im-
plicated in the modulation of instrumental conditioning and delayed
reinforcement (Ambroggi et al., 2011; Cardinal and Cheung, 2005;
Corbit et al., 2001; Di Chiara, 2002). Further studies will be required
to assess the specific roles of neurosteroids and 5αRs in these two
regions. Second, our animal models were based on acute and sub-
chronic administration of a high FIN dose; while these preparations
are useful to assess the potential implications of the NAcc proteome
in the behavioral effects of FIN, they bear only limited face, con-
struct and predictive validity with respect to the conditions secondary
to FIN treatment in humans; furthermore, the relevance of our find-
ings to the underpinnings of PFS is limited, given that the present
study did not include the assessment of enduring effects of FIN af-
ter its discontinuation. Finally, our studies were only limited to the
NAcc; however, other regions, such as the prefrontal cortex, may
be involved in the behavioral effects of FIN (Devoto et al., 2012).
These limitations notwithstanding, our results showed that FIN treat-
ment affected the expression of a number of accumbal proteins in-
volved in key functional processes, such as regulation of GABAer-
gic neurotransmission, as well as steroid and pyrimidine metabolism.
These findings may prove crucial to understanding the neurochemical
mechanisms of FIN’s neuropsychiatric side effects, as well as its po
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tential therapeutic properties for neurological and mental disorders
(Paba et al., 2011).
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